1072906-04-7

Basic information

• Product Name: EthanaMine, 2-(5-broMo-2-nitrophenoxy)-N,N-diMethyl-
• Synonyms: EthanaMine, 2-(5-broMo-2-nitrophenoxy)-N,N-diMethyl-;2-(5-BROMO-2-NITROPHENOXY)-N,N-DIMETHYLETHANAMINE
• CAS NO: 1072906-04-7
• Molecular Formula: C₁₀H₁₃BrN₂O₃
• Molecular Weight: 289.12582
• Mol File: 1072906-04-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: EthanaMine, 2-(5-broMo-2-nitrophenoxy)-N,N-diMethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: EthanaMine, 2-(5-broMo-2-nitrophenoxy)-N,N-diMethyl-(1072906-04-7)
• EPA Substance Registry System: EthanaMine, 2-(5-broMo-2-nitrophenoxy)-N,N-diMethyl-(1072906-04-7)

Safety Data

• Hazardous Substances Data: 1072906-04-7(Hazardous Substances Data)

Upstream product

• 108-01-0 2-(N,N-dimethylamino)ethanol 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Downstream Products

• 1072906-05-8 4-bromo-2-(2-(dimethylamino)ethoxy)aniline 
• 1219729-17-5 C₂₃H₃₃BrN₄O₃ 
• 1219731-98-2 C₁₁H₁₃BrN₂O₂ 
• 1219722-72-1 3-(2-(2-(dimethylamino)ethoxy)-4-(1H-pyrazol-4-yl)phenyl)-1-(2-(dimethylamino)ethyl)-1-(3-methoxybenzyl)urea 
• 1072906-07-0 2-(2-(dimethylamino)ethoxy)-4-(1H-pyrazol-4-yl)aniline 
• 1623130-33-5 N,N-dimethyl-2-(2-nitro-5-(1H-pyrazol-4-yl)phenoxy)ethanamine 
• 1094472-13-5 SR 3850 

Relevant articles and documents

Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors

ROCK1 and ROCK2 are highly homologous isoforms. Accumulated studies indicate that they have distinct different functions, and the development of isoform selective ROCK inhibitors will pave new roads for the treatment of various diseases. In this work, a series of amide-chroman derivatives were synthesized and biologically evaluated in order to develop potent and isoform selective ROCK2 inhibitors. Remarkably, (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide ((S)-7c) possessed ROCK2 inhibitory activity with an IC50 value of 3 nM and 22.7-fold isoform selectivity (vs. ROCK1). Molecular docking indicated that hydrophobic interactions were the key element for the high potency and isoform selectivity of (S)-7c. The binding free energies predicted by MM/GBSA were in good agreement with the experimental bioactivities, and the analysis of individual energy terms suggested that residue Lys105 in ROCK1 or Lys121 in ROCK2 was the key residue for the isoform selectivity of (S)-7c.

Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors

RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (～7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.

UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS

The invention is directed to compounds that can inhibit the bioactivity of one or more kinases such as any of Rho kinases, PKB (Akt) kinases, p70S6K kinase, LIM kinases, or IKK kinases, to methods of use of those compounds, and to methods of preparation of those compounds The inventive compounds can be used In the treatment of a variety of medical malconditions.